In fact, in the phase III KEYNOTE-024 trial, untreated subjects with advanced NSCLC whose tumours expressed high levels of PD-L1 (tumour proportion score, TPS, ≥ 50%), which represent about 1/3 of the screened population, were randomised to pembrolizumab or platinum-based chemotherapy [83]. Here, CD274 is linked to non-small cell lung carcinoma.